
Christopher J Mcdougle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5377323/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal of Medicine, 2002, 347, 314-321.	27.0	1,379
2	A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. Archives of General Psychiatry, 1996, 53, 1001.	12.3	522
3	Parent-Rated Anxiety Symptoms in Children with Pervasive Developmental Disorders: Frequency and Association with Core Autism Symptoms and Cognitive Functioning. Journal of Abnormal Child Psychology, 2008, 36, 117-128.	3.5	423
4	Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry, 2005, 162, 1142-1148.	7.2	411
5	A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders. Archives of General Psychiatry, 1998, 55, 633.	12.3	356
6	Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2009, 48, 1143-1154.	0.5	279
7	Increased Prevalence of Familial Autoimmunity in Probands With Pervasive Developmental Disorders. Pediatrics, 2003, 112, e420-e420.	2.1	222
8	Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal of Clinical Psychopharmacology, 1999, 19, 37-44.	1.4	199
9	Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 921-927.	0.5	170
10	Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 2000, 30, 427-435.	2.7	150
11	Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. Journal of Child and Adolescent Psychopharmacology, 2005, 15, 869-884.	1.3	147
12	Clomipramine in Autism: Preliminary Evidence of Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 746-750.	0.5	144
13	Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal of Psychiatry, 2015, 172, 1197-1206.	7.2	143
14	Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. Biological Psychiatry, 2007, 61, 545-550.	1.3	142
15	A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2001, 11, 267-277.	1.3	133
16	Sertraline in Adults With Pervasive Developmental Disorders. Journal of Clinical Psychopharmacology, 1998, 18, 62-66.	1.4	121
17	Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data. American Journal of Psychiatry, 2004, 161, 1125-1127.	7.2	115
18	Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 599-610.	1.3	112

#	Article	IF	CITATIONS
19	Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 233-241.	1.3	109
20	AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 589-598.	1.3	102
21	Maternal and early postnatal immune activation produce sex-specific effects on autism-like behaviors and neuroimmune function in mice. Scientific Reports, 2019, 9, 16928.	3.3	98
22	Clomipramine in Adults with Pervasive Developmental Disorders: A Prospective Open-Label Investigation. Journal of Child and Adolescent Psychopharmacology, 1997, 7, 109-121.	1.3	94
23	Psychopharmacological interventions in autism spectrum disorder. Expert Opinion on Pharmacotherapy, 2016, 17, 937-952.	1.8	93
24	A Naturalistic Retrospective Analysis of Psychostimulants in Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 49-56.	1.3	90
25	Toward an immune-mediated subtype of autism spectrum disorder. Brain Research, 2015, 1617, 72-92.	2.2	84
26	Trichotillomania. American Journal of Clinical Dermatology, 2001, 2, 327-333.	6.7	80
27	Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology, 2014, 231, 1023-1036.	3.1	80
28	A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism, 2016, 7, 26.	4.9	79
29	Women and Autism Spectrum Disorder: Diagnosis and Implications for Treatment of Adolescents and Adults. Current Psychiatry Reports, 2019, 21, 22.	4.5	79
30	A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: Current state and future research opportunities. Neuroscience and Biobehavioral Reviews, 2015, 52, 56-73.	6.1	74
31	An exploration of concomitant psychiatric disorders in children with autism spectrum disorder. Comprehensive Psychiatry, 2019, 88, 57-64.	3.1	72
32	Multidisciplinary Assessment and Treatment of Self-Injurious Behavior in Autism Spectrum Disorder and Intellectual Disability: Integration of Psychological and Biological Theory and Approach. Journal of Autism and Developmental Disorders, 2015, 45, 1541-1568.	2.7	66
33	Maternal and Early Postnatal Immune Activation Produce Dissociable Effects on Neurotransmission in mPFC–Amygdala Circuits. Journal of Neuroscience, 2018, 38, 3358-3372.	3.6	65
34	Developmental Disabilities Modification of the Children's Global Assessment Scale. Biological Psychiatry, 2007, 61, 504-511.	1.3	64
35	Development of a parent training program for children with pervasive developmental disorders. Behavioral Interventions, 2007, 22, 201-221.	1.0	61
36	Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 482-493.	1.3	61

#	Article	IF	CITATIONS
37	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 415-423.	0.5	61
38	Overweight and obese status in children with autism spectrum disorder and disruptive behavior. Autism, 2018, 22, 450-459.	4.1	53
39	A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology, 2018, 43, 1772-1778.	5.4	52
40	A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism, 2016, 7, 2.	4.9	51
41	Neurochemistry in the pathophysiology of autism. Journal of Clinical Psychiatry, 2005, 66 Suppl 10, 9-18.	2.2	48
42	Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. Paediatric Drugs, 2001, 3, 927-942.	3.1	47
43	Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. Journal of Psychiatric Research, 2014, 59, 220-228.	3.1	46
44	Sex-dependent neurobiological features of prenatal immune activation via TLR7. Molecular Psychiatry, 2020, 25, 2330-2341.	7.9	43
45	Perinatal Immune Activation Produces Persistent Sleep Alterations and Epileptiform Activity in Male Mice. Neuropsychopharmacology, 2018, 43, 482-491.	5.4	43
46	A Pilot Study of Autism-Specific Care Plans During Hospital Admission. Pediatrics, 2016, 137, S196-S204.	2.1	37
47	d-Cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism, 2017, 8, 2.	4.9	35
48	Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Journal of Clinical Psychiatry, 2008, 69 Suppl 4, 15-20.	2.2	35
49	Pharmacotherapy of Down syndrome. Expert Opinion on Pharmacotherapy, 2018, 19, 1875-1889.	1.8	33
50	Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD). Neuropsychopharmacology, 2020, 45, 90-103.	5.4	32
51	Neurodevelopmental Disorders Among Publicly or Privately Insured Children in the United States. JAMA Psychiatry, 2022, 79, 232.	11.0	31
52	Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder. Psychopharmacology, 2019, 236, 3045-3061.	3.1	30
53	Brief Report: Autism Spectrum Disorder and Substance Use Disorder: A Review and Case Study. Journal of Autism and Developmental Disorders, 2016, 46, 2514-2519.	2.7	29
54	Input from our Readers. CNS Spectrums, 1998, 3, 22-23.	1.2	27

#	Article	IF	CITATIONS
55	Genetics of Childhood Disorders: XLIV. Autism, Part 3: Psychopharmacology of Autism. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, 41, 1380-1383.	0.5	26
56	Clinical Correlates of Parenting Stress in Children with Autism Spectrum Disorder and Serious Behavioral Problems. Journal of Child and Family Studies, 2019, 28, 2069-2077.	1.3	26
57	Evidence-Based Treatments for Autism Spectrum Disorder. Current Treatment Options in Psychiatry, 2015, 2, 38-56.	1.9	25
58	A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 397-401.	1.3	25
59	Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 555-564.	1.3	24
60	Assessment of Speech and Fine Motor Coordination in Children With Autism Spectrum Disorder. IEEE Access, 2020, 8, 127535-127545.	4.2	24
61	Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders. CNS Drugs, 1998, 9, 213-232.	5.9	23
62	Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. Journal of Autism and Developmental Disorders, 1999, 29, 87-91.	2.7	23
63	Rapid clinical deterioration in an individual with Down syndrome. American Journal of Medical Genetics, Part A, 2016, 170, 1899-1902.	1.2	23
64	Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 91-94.	1.3	23
65	Epigenetics of Autism Spectrum Disorder: Histone Deacetylases. Biological Psychiatry, 2022, 91, 922-933.	1.3	23
66	Phenotypic differences in individuals with autism spectrum disorder born preterm and at term gestation. Autism, 2015, 19, 758-763.	4.1	22
67	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders. JAMA Internal Medicine, 2022, 182, 522.	5.1	22
68	Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Seminars in Pediatric Neurology, 2020, 35, 100835.	2.0	20
69	The Effects of Aripiprazole on Electrocardiography in Children with Pervasive Developmental Disorders. Journal of Child and Adolescent Psychopharmacology, 2012, 22, 277-283.	1.3	19
70	Attention Bias to Emotional Faces Varies by IQ and Anxiety in Williams Syndrome. Journal of Autism and Developmental Disorders, 2016, 46, 2174-2185.	2.7	19
71	Bone microarchitecture in adolescent boys with autism spectrum disorder. Bone, 2017, 97, 139-146.	2.9	19
72	Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 2003, 64 Suppl 4, 16-25.	2.2	18

#	Article	IF	CITATIONS
73	Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 125-131.	1.3	17
74	Bone Accrual in Males with Autism Spectrum Disorder. Journal of Pediatrics, 2017, 181, 195-201.e6.	1.8	16
75	Providing Inpatient Medical Care to Children With Autism Spectrum Disorder. Hospital Pediatrics, 2020, 10, 918-924.	1.3	16
76	Mobile device applications and treatment of autism spectrum disorder: a systematic review and meta-analysis of effectiveness. Archives of Disease in Childhood, 2020, 105, 458-462.	1.9	15
77	Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). Contemporary Clinical Trials, 2020, 98, 106103.	1.8	14
78	Agitation in Patients With Autism Spectrum Disorder Admitted to Inpatient Pediatric Medical Units. Pediatrics, 2020, 145, S108-S116.	2.1	14
79	A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology, 2022, 47, 1263-1270.	5.4	13
80	Neuroinflammation and Autism: Toward Mechanisms and Treatments. Neuropsychopharmacology, 2013, 38, 241-242.	5.4	11
81	Challenges in the Medical Care of Patients With Autism Spectrum Disorder: The Role of the Consultation-Liaison Psychiatrist. Psychosomatics, 2019, 60, 435-443.	2.5	11
82	Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome. Psychiatric Genetics, 2019, 29, 51-56.	1.1	11
83	Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness. Expert Opinion on Drug Safety, 2021, 20, 293-306.	2.4	9
84	The pathophysiology and treatment of autism. Current Psychiatry Reports, 2001, 3, 101-108.	4.5	8
85	Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome. American Journal of Medical Genetics, Part A, 2020, 182, 1913-1922.	1.2	8
86	Parent Description of Anxiety in Angelman Syndrome. Journal of Autism and Developmental Disorders, 2022, 52, 3612-3625.	2.7	8
87	Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder. Current Psychiatry Reports, 2021, 23, 79.	4.5	8
88	ECT in an Adolescent with Down Syndrome and Treatment-Refractory Major Depressive Disorder. Journal of Developmental and Physical Disabilities, 2002, 14, 291-295.	1.6	7
89	No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 900-908.	1.3	7
90	Sensitivity of the modified Children's Yale–Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. Autism, 2016, 20, 145-152.	4.1	7

Christopher J McDougle

#	Article	IF	CITATIONS
91	Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series. Journal of Autism and Developmental Disorders, 2020, 50, 676-682.	2.7	6
92	Immune Modulatory Treatments for Autism Spectrum Disorder. Seminars in Pediatric Neurology, 2020, 35, 100836.	2.0	6
93	Repetitive Thoughts and Repetitive Behaviors in Williams Syndrome. Journal of Autism and Developmental Disorders, 2022, 52, 852-862.	2.7	6
94	Comparison of Services for Autism Spectrum Disorder in Massachusetts with Those in Seoul. Journal of Korean Medical Science, 2019, 34, e288.	2.5	6
95	A Virtually Delivered Adapted Cognitive-Behavioral Therapy Group for Adults With Williams Syndrome and Anxiety. Cognitive and Behavioral Practice, 2023, 30, 669-677.	1.5	6
96	Another Step Toward Defining an Immune-Mediated Subtype of Autism Spectrum Disorder. JAMA Network Open, 2018, 1, e180280.	5.9	5
97	Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2022, 52, 4164-4171.	2.7	5
98	Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series. Journal of Autism and Developmental Disorders, 2018, 48, 947-952.	2.7	5
99	N-Acetylcysteine for Neuropsychiatric Symptoms in a Woman With Williams Syndrome. Journal of Child Neurology, 2014, 29, NP135-NP138.	1.4	4
100	Sleep and EEG biomarkers as avenues toward new treatment approaches in Angelman syndrome. Neuropsychopharmacology, 2020, 45, 238-239.	5.4	4
101	Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder. Journal of Child and Family Studies, 2021, 30, 784-792.	1.3	4
102	Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases. Journal of Developmental and Behavioral Pediatrics, 2022, 43, 38-43.	1.1	4
103	Case Reports: Clozapine for the Treatment of Catatonia in Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 2022, 52, 2855-2858.	2.7	4
104	Atypical Antipsychotic-Induced Weight Gain in Children and Adolescents. JAMA Psychiatry, 2016, 73, 899.	11.0	3
105	Stimulant intolerance in children with Angelman syndrome with hyperactivity: a case series. Psychiatric Genetics, 2022, 32, 80-86.	1.1	3
106	Serotonin and dopamine transporter binding in children with autism. Developmental Medicine and Child Neurology, 2008, 50, 565-565.	2.1	2
107	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
108	Post-traumatic stress disorder following cardiac surgery: A case report of a nine-year-old female with Williams syndrome. Journal of Intellectual and Developmental Disability, 2019, 44, 244-247.	1.6	1

#	Article	IF	CITATIONS
109	New-Onset Abnormal Vocalizations in an Adult Woman With Down Syndrome. Psychosomatics, 2020, 61, 804-807.	2.5	1
110	Paroxysmal oculogyric dystonia associated with a de novo 3q29 microdeletion. Psychiatric Genetics, 2020, 30, 119-123.	1.1	0
111	A rational pharmacologic approach toward a biologically meaningful subtype of autism spectrum disorder. Jornal De Pediatria, 2021, 97, 1-3.	2.0	0
112	Evaluation and Treatment of New-Onset Psychotic Symptoms in a Patient with Autism Spectrum Disorder and Multiple Autoimmune Disorders. Harvard Review of Psychiatry, 2021, 29, 378-387.	2.1	0
113	Functional Neurological Symptom Disorder in Williams Syndrome: Case Series and Review of Relevant Literature. Journal of the Academy of Consultation-Liaison Psychiatry, 2021, , .	0.4	0